{"id":"W4379282010","doi":"10.1200/jco.2023.41.16_suppl.4518","title":"First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Pembrolizumab; Medicine; Chromophobe cell; Clear cell; Lenvatinib; Renal cell carcinoma; Histology; Internal medicine; Oncology; Clinical endpoint; Cabozantinib; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003462887,0.0009461874,0.001437764,0.0002714544,0.0002753833,0.0008661357,0.0006046143,0.0008728952,0.002546454],"category_scores_gemma":[0.001256871,0.0004018007,0.001328088,0.0003117658,0.0003312808,0.0007097428,0.000422314,0.001679109,0.0007263104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007539321,"about_ca_system_score_gemma":0.001130546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007346908,"about_ca_topic_score_gemma":0.002118565,"domain_scores_codex":[0.9992425,0.0003913817,0.00005006292,0.0001094639,0.0001134801,0.00009312702],"domain_scores_gemma":[0.9991535,0.0001077627,0.000241358,0.00007832683,0.00008348277,0.0003355589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.617972,0.05472962,0.05802522,0.003107605,0.009343671,0.0005451074,0.000508394,0.002823291,0.04888393,0.0003713153,0.01857338,0.1851164],"study_design_scores_gemma":[0.5479174,0.2982772,0.1273466,0.0002075382,0.005028523,0.001216157,0.0001294664,0.001567322,0.004993816,0.0002658838,0.01299512,0.00005498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814054,0.008917974,0.0006170662,0.0006510438,0.0001242853,0.002010074,0.003916504,0.00008681561,0.002270826],"genre_scores_gemma":[0.9773704,0.004789871,0.001531501,0.001617158,0.0002222806,0.001433424,0.01012394,0.00004007043,0.00287135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003462887,"threshold_uncertainty_score":0.01831371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1672484810168807,"score_gpt":0.4674915050845849,"score_spread":0.3002430240677041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}